
CLAIMS

1. Use of a compound of the formula:



(hereinafter: Compound A) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, wherein the dose of Compound A in the medicament ranges from about 1 to 25 mg per day.

2. The use according to claim 1, wherein the dose of said compound in the medicament ranges from about 5 to 10 mg per day.


3. The use according to claim 1 or 2, wherein the dose of said compound in the medicament is about 5 mg per day or about 10 mg per day.

4. The use according to any one of the preceding claims, wherein the medicament is to be administered to subjects in need thereof for 1, 5, 10, 20, 40, 52, 100, or 200 weeks.

5. The use according to any one of the preceding claims, wherein the medicament is to be administered to subjects in need thereof for at least one week, preferably at least three weeks.

6. The use according to any one of the preceding claims, wherein the medicament is for the treatment of subjects suffering from or having an increased risk for hyperlipidemia or mixed dyslipidemia.

7. Use of a pharmaceutical composition in the manufacture of a medicament for the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, wherein the composition comprises a therapeutically effective amount of the compound:



(hereinafter: Compound A) or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable excipient, wherein the medicament is to be administered orally to subjects need in thereof and wherein the dose of Compound A in the medicament ranges from about 1 to 25 mg per day.

8. The use according to claim 7, wherein the dose of Compound A in the medicament ranges from about 5 to 10 mg per day.

9. The use according to claim 7 or 8, wherein the dose of Compound A in the medicament is about 5 mg per day or about 10 mg per day.

10. The use according to any one of claims 7 to 9, wherein the medicament is to be administered to the subjects in need thereof for 1, 5, 10, 20, 40, 52, 100, or 200 weeks.

11. The use according to any one of claims 7 to 10, wherein the medicament is to be administered to the subjects in need thereof for at least one week, preferably at least three weeks.

12. The use according to any one of claims 7 to 11, wherein the medicament is formulated as a single unit dosage form.

13. The use according to claim 12, wherein the single unit dosage form comprises about 1 to 25 mg, preferably about 5 to 10 mg of Compound A, optionally about 5 mg or about 10 mg of Compound A.

14. The use according to any one of claims 7 to 13, wherein the medicament is formulated as a liquid oral dosage form or as a solid oral dosage form, such as a tablet or capsule.

15. The use according to any one of claims 7 to 14, wherein the medicament is for the treatment of subjects suffering from or having an increased risk for hyperlipidemia or mixed dyslipidemia.